I'm interested to hear your reasoning about lack of re-rate post 008 (if highly successful). Is this not the fist trial (given that SAS is in no way a trial) into the DM qualities of the drug? Could it be a lack of confidence in what management releases? Must say, going back over the history of the last 3 years, this is one of the most amateurish management teams in biotech.
Ann: Investor Presentation - $66m Capital Raise, page-55
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 29.5¢ | $34.55K | 115.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 40478 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |